NICE changes its mind on Forest’s Colobreathe for cystic fybrosis
This article was originally published in Scrip
Executive Summary
Continuing its work on cystic fibrosis (CF), NICE, the health technology appraisal institute for England and Wales, has reversed its earlier negative stance on Forest Laboratories' Colobreathe (colistimethate sodium DPI), now recommending it as a treatment option for lung infections in patients with the disease, albeit under certain circumstances.